Acelity L.P. Inc. 10-Q Quarterly Report May 2015


•	Adjusted EBITDA from continuing operations¹ of $165.8 million, grew 7.7% versus the prior-year period and 10.5% on a constant currency basis, achieving an Adjusted EBITDA margin of 37.3%


•	Loss from continuing operations improved to $4.5 million compared to $47.1 million in the prior-year period

Operational Highlights


•	Celebrated the 20th anniversary of Acelity’s revolutionary V.A.C.^® Therapy technology with record level of seasonally adjusted units in use


•	Launched two innovative product offerings: Nanova™, an advanced wound dressing enhanced by NPWT, and the industry-first iOn Healing™ mobile application designed to provide wound care clinicians with a suite of tools to improve customer support and increase productivity


•	Won arbitration with Vital Needs (“VNI”); the arbitration panel found that KCI has no liability for any of the claims asserted by VNI


•	Successfully amended senior secured credit facility to provide enhanced financial flexibility

Joe Woody, President and Chief Executive Officer, commented, “twenty years ago, we introduced the revolutionary V.A.C.^® Therapy System which transformed the wound care landscape. This innovative technology has become the treatment of choice around the world, supported by more published clinical evidence than any other form of NPWT on the market and has treated more than 9 million wounds worldwide.”

“Our strong performance in the first quarter was driven by our North American Advanced Wound Therapeutics devices business, which delivered double-digit growth and achieved the highest seasonally adjusted volumes in the history of the Company. We are well positioned to build on this successful expansion of our core market, adapt to new payment models in the U.S. and abroad, and reduce the total overall cost of care. These operational successes, coupled with our relentless focus on balancing cost control with execution, position the Company to drive long-term value creation as a leading, globally diversified healthcare company.”

The following information was filed by Acelity L.P. Inc. on Wednesday, April 29, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1557939/000155793915000028/a2015q110q.htm

View differences made from one quarter to another to evaluate Acelity L.P. Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Acelity L.P. Inc..

Continue

Assess how Acelity L.P. Inc.'s management team is paid from their Annual Proxy

Acelity L.P. Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Acelity L.P. Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

CIK: 1557939
Form Type: 10-Q Quarterly Report
Accession Number: 0001557939-15-000028
Submitted to the SEC: Fri May 01 2015 9:38:23 PM EST
Accepted by the SEC: Mon May 04 2015
Period: Tuesday, March 31, 2015
Industry: Surgical And Medical Instruments And Apparatus